RIOK1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL16793996	1.00	1/20
SCHEMBL16793994	0.86	1/20
SCHEMBL16794435	0.85	1/20
SCHEMBL16794292	0.84	1/20
SCHEMBL16794367	0.83	1/20
SCHEMBL18170405	0.81	1/20
SCHEMBL16794020	0.81	1/20
SCHEMBL16794027	0.81	1/20
SCHEMBL16794172	0.80	1/20
SCHEMBL16794280	0.79	1/20
SCHEMBL16794024	0.79	1/20
SCHEMBL16794321	0.78	1/20
SCHEMBL16794459	0.78	1/20
SCHEMBL18170383	0.77	1/20
SCHEMBL16793960	0.77	1/20
SCHEMBL16814059	0.76	1/20
SCHEMBL18170530	0.76	1/20
SCHEMBL18170531	0.76	1/20
SCHEMBL16794205	0.76	1/20
SCHEMBL16794178	0.76	1/20

Clinical trials — most relevant to RIOK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	PHASE1/PHASE2	COMPLETED
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma	PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor	PHASE1/PHASE2	NOT_YET_RECRUITING
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer	PHASE2	COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
KRAS Wild-type Metastatic Colorectal Cancer Trial	PHASE1	COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Molecular Analysis of Thoracic Malignancies	nan	ENROLLING_BY_INVITATION
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients	nan	COMPLETED
MEHMO Natural History and Biomarkers	nan	RECRUITING
Biomarkers in Samples From Patients With Endometrial Cancer	nan	WITHDRAWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients	nan	COMPLETED
Detection of EGFR Mutation in Malignant Pleural Effusion of Lung Cancer Patients and Cancer Cell Lines Establishment	nan	UNKNOWN
Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a RIOK1 binder may also engage these)

Protein	Name	Similarity
Q922Q2	—	0.988	Q922Q2 →
RIOK3	Serine/threonine-protein kinase RIO3	0.980	landscape →
Q1RMT7	—	0.977	Q1RMT7 →
Q9DBU3	—	0.977	Q9DBU3 →
F1QDI9	—	0.974	F1QDI9 →
PI4KB	Phosphatidylinositol 4-kinase beta	0.974	landscape →
B1MTG7	—	0.972	B1MTG7 →
Q5ZKK7	—	0.971	Q5ZKK7 →
Q60HG1	—	0.971	Q60HG1 →
E9Q4Z2	—	0.971	E9Q4Z2 →
B0KWC1	—	0.970	B0KWC1 →
Q1RMT1	—	0.970	Q1RMT1 →
O08561	—	0.970	O08561 →
B2KI64	—	0.970	B2KI64 →
EEF2K	Eukaryotic elongation factor 2 kinase	0.969	landscape →
E9Q5G3	—	0.969	E9Q5G3 →
O02810	—	0.969	O02810 →
Q4G005	—	0.969	Q4G005 →
B3EX61	—	0.968	B3EX61 →
A4IID4	—	0.968	A4IID4 →
Q5RA62	—	0.968	Q5RA62 →
P49135	—	0.968	P49135 →
P70531	—	0.968	P70531 →
Q9UPW8	—	0.968	Q9UPW8 →
Q8IU60	—	0.968	Q8IU60 →
B9EJ86	—	0.967	B9EJ86 →
KIF23	Kinesin-like protein KIF23	0.967	landscape →
A9X1A0	—	0.967	A9X1A0 →
Q62768	—	0.967	Q62768 →
Q6GN16	—	0.967	Q6GN16 →